MYC and small cell lung carcinoma: Recently, several MYC inhibitors, including Omomyc, BET bromodomain inhibitor and Aurora kinase inhibitor, have been reported (Soucek et al., 2008; Delmore et al., 2011; Sos et al., 2012); therefore, the MYC family gene products could be druggable targets in SCLC cells with their activation.